British Journal of Haematology | Wiley Online Library
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial - The Lancet Haematology
Maintenance Therapy with Revlimid for Multiple Myelom
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed
Optimized dosing regimens for single-agent lenalidomide in... | Download Scientific Diagram
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Treatment schema for newly diagnosed multiple myeloma and commonly used... | Download Scientific Diagram
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
547-Lenalidomide and dexamethasone oral | eviQ
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Ixazomib in Combination with Cyclophosphamide/Dexamethasone or Lenalidomide/ Dexamethasone | Research To Practice
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
REVLIMID® (lenalidomide) - Official Patient Website
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Relapsed: D + RD Treatment | DARZALEX® IV (daratumumab)
Dosing and Administration for the NINLARO® (ixazomib) Regimen
